Orthogon Therapeutics is a drug development company developing antiviral drugs for immune-suppressed patients.
Orthogon Therapeutics has raised $11.0M in total funding. The most recent round was Undisclosed. The last funding was announced in April 2026.
Orthogon Therapeutics's investors include Over-the-Rhine Ventures, Holbrook Angels of Boston.
Orthogon Therapeutics is headquartered in Canton, United States.
Orthogon Therapeutics is a drug development company developing antiviral drugs for immune-suppressed patients.
Orthogon Therapeutics is at the Undisclosed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Orthogon Therapeutics — Funding & Investors." VCBacked, April 17, 2026, https://www.vcbacked.co/company/orthogon-therapeutics. Accessed July 22, 2026.
VCBacked. (2026). Orthogon Therapeutics — Funding & Investors. Retrieved July 22, 2026, from https://www.vcbacked.co/company/orthogon-therapeutics
{{cite web |title=Orthogon Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/orthogon-therapeutics |website=VCBacked |access-date=July 22, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated